Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “WHO Grade 3 Glioma With IDH1 Mutation”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Looking for participantsNCT06161974
What this trial is testing

Study of Olutasidenib and Temozolomide in HGG

Who this might be right for
High Grade GliomaAstrocytomaAstrocytoma, Grade III+16 more
Rigel Pharmaceuticals 60
Not applicableActive Not RecruitingNCT01358058
What this trial is testing

Proton Radiation Therapy for Gliomas

Who this might be right for
Low Grade GliomaWHO Grade 3 Glioma With IDH1 MutationWHO Grade 3 Glioma With 1p/19q Codeletion
Massachusetts General Hospital 63
Early research (Phase 1)Active Not RecruitingNCT03749187
What this trial is testing

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Who this might be right for
GlioblastomaIDH1 Gene MutationIDH2 Gene Mutation+7 more
University of California, San Francisco 78
Testing effectiveness (Phase 2)Active Not RecruitingNCT03212274
What this trial is testing

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
Advanced Malignant Solid NeoplasmGlioblastomaRecurrent Cholangiocarcinoma+4 more
National Cancer Institute (NCI) 89
Large-scale testing (Phase 3)Active Not RecruitingNCT04576117
What this trial is testing

Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Who this might be right for
Recurrent Low Grade AstrocytomaRecurrent WHO Grade 2 GliomaRefractory Low Grade Astrocytoma+2 more
National Cancer Institute (NCI) 300
Testing effectiveness (Phase 2)Study completedNCT03914742
What this trial is testing

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Who this might be right for
IDH1 MutationIDH2 MutationRecurrent Glioblastoma+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 67